Longer Overall Survival in Metastatic TNBC With Pembrolizumab - Medpage Today

New Developments in Triple-Negative Breast Cancer Therapies - Medpage TodayПодробнее

Latest on Immunotherapy in Triple-Negative Breast Cancer - Medpage TodayПодробнее

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancerПодробнее

Trodelvy Improves QOL in Triple-Negative Breast Cancer - Medpage TodayПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее

CDK4/6 Inhibitor Maintained OS Benefit in Advanced Breast Cancer - Medpage TodayПодробнее

New directions in immunotherapy for improving outcomes in TNBCПодробнее

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBCПодробнее

Drs. Kuerer & McArthur discuss the lastest #TNBC updates from #SSO2022 - https://bit.ly/3IBS0zkПодробнее

Triple Negative Breast Cancer Update: Immunotherapy in stage 2-3 TNBC (KEYNOTE 522 Update)Подробнее

Secondary Endpoints From a Trial of Pembrolizumab Plus Chemotherapy for Metastatic TNBCПодробнее

Harnessing the Immune System in the Treatment of Triple-Negative Breast CancerПодробнее

New Long-Term Study Promotes Keytruda as a Treatment for Aggressive Breast CancerПодробнее

Emerging immunotherapy beyond checkpoint inhibitors for TNBCПодробнее

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OSПодробнее

Dr. Sara Tolaney on Eribulin Plus Pembrolizumab for Metastatic Triple-Negative Breast CancerПодробнее

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...Подробнее

Open Mic: What Study Will You Take Home? - Medpage TodayПодробнее